anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Arteriovenous fistula (AVF) is the optimal form of vascular access for most haemodialysis dependant patients; however, it is prone to the formation of stenoses that compromise utility and longevity. Whilst there are many factors influencing the development of these stenoses, pathological flow-related phenomena may also incite the formation of intimal hyperplasia, and hence a stenosis. Repeated CFD-derived resistance was calculated for six patient who had a radiocephalic AVF, treated with an interwoven nitinol stent around the juxta-anastomotic region to address access dysfunction. A three-dimensional freehand ultrasound system was used to obtain patient-specific flow profiles and geometries, before performing CFD simulations to replicate the flow phenomena in the AVF, which enabled the calculation of CFD-derived resistance. We presented six patient cases who were examined before and after treatment and our results showed a 77% decrease in resistance, recorded after a surgical intervention to address access dysfunction. Problematic AVFs were found to have high resistance, particularly in the venous segment. AVFs with no reported clinical problems, and clinical patency, had low resistance in the venous segment. There did not appear to be any relationship with clinical problems/patency and resistance values in the arterial segment. Identifying changes in resistance along the circuit allowed stenoses to be identified, independent to that determined using standard sonographic criteria. Our exploratory study reveals thatCFD-derived resistance is a promising metric that allows for non-invasive identification of diseased AVFs. The pipeline analysis enabled regular surveillance of AVF to be studied to aid with surgical planning and outcome, further exhibiting its clinical utility.
Neurodegenerative diseases pose a formidable challenge to medical research, demanding a nuanced understanding of their progressive nature. In this regard, latent generative models can effectively be used in a data-driven modeling of different dimensions of neurodegeneration, framed within the context of the manifold hypothesis. This paper proposes a joint framework for a multi-modal, common latent generative model to address the need for a more comprehensive understanding of the neurodegenerative landscape in the context of Parkinson's disease (PD). The proposed architecture uses coupled variational autoencoders (VAEs) to joint model a common latent space to both neuroimaging and clinical data from the Parkinson's Progression Markers Initiative (PPMI). Alternative loss functions, different normalization procedures, and the interpretability and explainability of latent generative models are addressed, leading to a model that was able to predict clinical symptomatology in the test set, as measured by the unified Parkinson's disease rating scale (UPDRS), with R2 up to 0.86 for same-modality and 0.441 cross-modality (using solely neuroimaging). The findings provide a foundation for further advancements in the field of clinical research and practice, with potential applications in decision-making processes for PD. The study also highlights the limitations and capabilities of the proposed model, emphasizing its direct interpretability and potential impact on understanding and interpreting neuroimaging patterns associated with PD symptomatology.
Product for stiffening and tinting hair. For use, no preparation is needed, it is supplied ready for use. Its action is especially long-lasting. It consists of a mixture of: nutgall, olive oil, copper oxide and cloves. To this product, diluted in hot water by the user, artichoke leaves are added. Application is carried out, after three and a half hours of soaking, in the form of a paste.
Up to 3 COS cycles (also called treatment cycles) were performed, each including the following: A single injection of 150 µg corifollitropin alfa was administered on Day 2 or 3 of the menstrual cycle (Stimulation Day 1). Administration of GnRH antagonist (0.25 mg/day) started on Stimulation Day 5 or 6 and continued through day of administration of recombinant Human Chorion Gonadotropin (\[rec\]hCG) (5,000-10,000 IU/250 µg). Administration of (rec)hCG occurred when 3 follicles ≥17 mm were observed on ultrasound scan (USS). Daily dosing with Follicle Stimulating Hormone (FSH) (not to exceed 225 IU/day) began on Stimulation Day 8 and continued up to day of (rec)hCG administration. Progesterone for luteal phase support was administered starting on the day of oocyte pick-up (34-36 hours after \[rec\]hCG) and continued for approximately 6 weeks. After COS cycles 1 and 2, Frozen-Thawed Embryo Transfer cycles (up to 3 after each COS cycle) could occur.
The dosage unit is used in the pharmeceutical indystry. It is convenient for picking up by patients who fing it difficulty to manipulate with hands or are suffering from rheumatism, arthritis and other diseases and has specific height and shape of the projecting parts of the unit such that to ensure a stable tilted position of the unit comprising an angle of 6 to 40° relative to the horizontal surface. It is a casing (1) in the shape of a triangular prism on whose opposite sides are formed hemispherical projection situated in the centre of the triangular wall (4) of the prism guaranteeing a slope of the casing (1) of an angle from 6 to 40°. Furthermore, the prism angles are rounded and its peripheral enges are chamfered. The casing itself can also have some other shape such as parallelipiped, pentagonal prism, cylinder, the form of the in cross section being elliptic,circular, disc- cube or capsule-like. The projections on the casing faces have hemispherical form or the form of a cube, parallelepiped, respectively tri-, tetra- or pent-agular and in case of hemispherical projections it can have one, two, three or four faces.
Opening remarks: These guidelines are the result of discussions within a diverse group of RSA researchers. They were approved in December 2023 by the board and selected members of the International Radiostereometry Society to update the guidelines by Valstar et al. [1]. By adhering to these guidelines, RSA studies will become more transparent and consistent in execution, presentation, reporting, and interpretation. Both authors and reviewers of scientific papers using RSA may use these guidelines, summarized in the Checklist, as a reference. Deviations from these guidelines should have the underlying rationale stated.
Chronic kidney disease (CKD) is associated with increased risk of cardiovascular disease and mortality as well as impaired quality of life. Participants of this study all have severe CKD, defined as estimated glomerular filtration rate \< 30 ml/min per 1.73 m\^2. Stress ergometry, echocardiography, ultrasound assessment of arterial intima-media thickness, lateral lumbar radiograph, ECG, laboratory tests and quality of life assessment were performed at the baseline of the study and will be repeated during follow-up. Atrial fibrillation and other cardiac arrhythmias as well as pulse wave velocity measurements will be explored. Diet diaries are gathered and analysed. The aim of the study is to identify factors associated with cardiovascular disease, quality of life and mortality in this cohort.
The high thrombus burden of the infarct-related artery (IRA) is associated with the adverse prognosis in ST-segment elevation myocardial infarction (STEMI) patients. Our objectives were to investigate the predictors and evaluate the prognosis of refractory thrombus in STEMI patients. A total of 1305 consecutive patients with STEMI who underwent primary percutaneous coronary intervention (pPCI) were screened. The refractory thrombus group (n = 15) was defined as IRA thrombolysis in myocardial infarction flow < grade 2 after multiple thrombus aspiration (TA). The control group (n = 45) was age- and sex-matched and was selected from the same batch of patients. Baseline hematologic indices were measured before the pPCI. The major adverse cardiovascular events (MACE) were recorded during follow-up. The refractory thrombus group had significantly higher red cell distribution width (RDW) at baseline compared with the control group (13.1 [12.4-13.7] vs 12.6 [12.3-12.8], P = .008). In multivariate logistic regression analysis, RDW was an independent predictor of refractory thrombus (odds ratio: 8.799, 95% CI: 1.240-62.454, P = .030). The area under the receiver-operating characteristic curve of the RDW was 0.730 (95%CI: 0.548-0.912, P = .008). During a mean period of 26 months follow-up, patients in the refractory thrombus group tended to have higher percent MACEs compared with patients in the control group (53.3% vs 6.7%, P < .001). In the present study, we found that the refractory thrombus in STEMI patients was associated with the worse prognosis and the increased RDW might be a potential independent predictor.
The invention relates to a composition for the treatment of the hair and the scalp when there is hair loss based on conventional cosmetic vehicles and additives, where the hair growth-promoting effect is based on the antiandrogenic effect of cyproterone acetate. This substance is suitable for reducing the androgenetic hair loss, which in women may also exist when there is no elevation of androgen levels in serum or collected urine, and for promoting hair growth. The invention also relates to a hair treatment process for the same purpose, which relates to the amount of hair lotion applied, the frequency of application and the type and mode of application. The percutaneous absorption of cyproterone acetate ensures blocking of the androgen receptors in the scalp without systemic side effects, which are scarcely avoidable on oral or parenteral administration (e.g. loss of libido, impotence, reversible sterility, gynaecomastia, thromboembolic complications, disturbances of liver function), occurring at the stated dosage. The target group for the hair lotion and the hair treatment process are men and pre- and post-menopausal women who have hair loss which is partly or mainly caused androgenetically and who wish to avoid the systemic effects of cyproterone acetate.
Takotsubo syndrome (TTS) has been suggested to be caused by catecholamine excess with myocardial inflammation-enhanced cardiac injury. Substantial morbidity and mortality have repeatedly been reported, even though reduced ejection fraction frequently recovers spontaneously. So far there is no evidence-based treatment available. In a clinically relevant mouse model of catecholamine-driven TTS, cyclosporine A (CsA) bolus therapy markedly improves outcome, likely mediated via suppression of calcineurin-driven inflammation. The investigators have thus designed a pilot multicentre randomized controlled trial (RCT) to investigate the impact of repetitive CsA bolus therapy vs. placebo in acute TTS patients with an increased risk of intrahospital complications and a 32% estimated 5-year mortality. As primary outcome myocardial damage will be compared between groups via high-sensitive Troponin T plasma area under the curve (AUC). Recovery of cardiac function, the extent of myocardial oedema at 72h, length of hospital-stay, 30-day-, and 1-year composite clinical outcome as well as psychosocial and quality of life self-assessment will be secondary endpoints. The results of this trial may reveal CsA as a first pathophysiology-driven treatment option of TTS and enable a phase III follow-up trial with outcome parameters as primary endpoint.
A ranolazine skeleton sustained-release tablet and a preparation method therefor. A regulatory layer is provided outside a drug layer in the tablet core of the ranolazine skeleton sustained-release tablet, so as to form a double-layer sustained-release tablet. The weight percentage of the drug layer in the whole tablet core is 60% to 95%, and the weight percentage of the regulatory layer in the whole tablet core is 5% to 40%. The drug layer is made of the following raw material components: ranolazine, a skeleton sustained-release material and other auxiliary materials. The weight percentage of each component accounting for the tablet weight is as follows: 35% to 90% of ranolazine, 3% to 40% of the skeleton sustained-release material, and 1% to 15% of the other auxiliary materials. The regulatory layer is made of the following raw material components: a skeleton sustained-release material and other auxiliary materials. The weight percentage of each component accounting for the tablet weight is as follows: 2% to 35% of the skeleton sustained-release material, and 1% to 15% of the other auxiliary materials. The preparation method comprises the following steps: 1) preparing drug layer particles; 2) preparing regulatory layer particles; and 3) pressing the prepared drug layer particles and the regulatory layer particles together into a double-layer tablet.
This is a combined clinical pharmacology and phase III study. The study is a prospective, open-label, multi-center study. Children 0 to \<18 years of age with iron deficiency anemia (IDA) with a) non-dialysis dependent chronic kidney disease (NDD-CKD) or b) who are intolerant or unresponsive to oral iron will be enrolled. The subjects will receive ferric derisomaltose/iron isomaltoside 1000 (Monoferric®) at single doses of 10 mg/kg or 20 mg/kg with a maximal dose of 1000 mg.

A total of 200 subjects will be enrolled. Of these will 24 be part of the PK assessment. PK-subjects will be included in cohorts of 4 with the oldest age group as the first and with ferric derisomaltose 10 mg/kg to be increased to 20 mg/kg for the next cohort. Thus 12 subjects will be treated with 10mg/kg and the remaining 188 subjects with 20mg/kg.
The transversus abdominis plane (TAP) technique, originally described by involves injection of local anaesthetic in the plane between the internal oblique and transversus abdominis muscle layers, with the aim of anaesthetising the intercostal nerves supplying the abdominal wall. Initially, the block used surface landmarks of the triangle of Petit (latissimus dorsi posteriorly, external oblique superiorly, iliac crest inferiorly) and a double fascial 'pop' (loss of resistance) to guide placement of the local anaesthetic. More recently, ultrasonography has been used to guide the delivery of the injectate into the appropriate plane, thereby increasing the accuracy of the Technique.

The duration of the TAB is limited to effect of administered local anesthetics. To prolong the block's duration, adjuvant medications were added to LA to magnify the effect of TAP block . Opiates such as morphine and tramadol have peripheral and central analgesic effects. Opiate receptors are present at the terminals of afferent peripheral nerves; therefore, administration of opiates peripherally might provide a significant analgesic effect.
PROBLEM TO BE SOLVED: To obtain the subject new compound, especially suitable as a UV filter for ultraviolet rays A and capable of protecting skin and hair of especially humans and animals from injurious actions of ultraviolet radiations. SOLUTION: This triazine compound is represented by formula I [R is a halogen, a linear or a branched chainlike 1-22C alkyl or a 1-22C alkoxy or a 1-22C hydroxyalkoxy, etc.; X2 and X3 are each independently a group represented by CONHR1 (R1 is H or a linear or a branched chainlike 1-22C alkyl, etc.), CN, etc.; X5 and X6 are each H, hydroxy, etc.], e.g. a compound represented by formula II. The compound represented by formula I is obtained by reacting 1mol each of an aniline compound represented by formula III or IV or a compound represented by the formula R-H with 1mol of cyanuric chloride. Thereby, the resultant compound is suitable as a sunscreen in each composition of cosmetics, medicines and animal medicines and can be used even in either a dissolved form or a finely pulverized form.
The efficacy of Paroxetine Capsules as a treatment for moderate to severe VMS associated with menopause was established in two Phase 3 studies (at a dose of 7.5 mg once daily at bedtime) in 1174 postmenopausal women with a minimum of 7-8 moderate to severe vasomotor symptoms per day at baseline (≥ 50 per week) for 30 days prior to receiving study drug.

Study 1 was a 12-week, randomized, double-blind, placebo-controlled clinical trial with a total of 606 postmenopausal women (average age 55 years, 65% Caucasian and 33% African American, 18% surgically menopausal and 82% naturally menopausal).

Study 2 was a 24-week, randomized, double-blind, placebo-controlled clinical trial with a total of 568 postmenopausal women (average age 54 years, 76% Caucasian and 22% African American, 20% surgically menopausal and 81% naturally menopausal).

The co-primary efficacy endpoints for both studies were the reduction from baseline in VMS frequency and severity at Weeks 4 and 12. Data from Study 1 showed a statistically significant reduction from baseline in the frequency of moderate to severe vasomotor symptoms at Week 4 and Week 12 and a statistically significant reduction in the severity of moderate to severe VMS at Week 4 for Paroxetine Capsules compared to placebo (Table 4). Data from Study 2 showed a statistically significant reduction from baseline in the frequency and severity of moderate to severe vasomotor symptoms at Week 4 and Week 12 for Paroxetine Capsules compared to placebo (Table 5).

Persistence of benefit at 24 weeks in Study 2 was evaluated with a responder analysis where responders were defined as those patients who achieved ≥ 50% reduction from baseline in the frequency of moderate to severe VMS at Week 24. The proportion of patients achieving a ≥ 50% reduction in the frequency of moderate to severe VMS from baseline to Week 24 was 48% in the Paroxetine Capsules group and 36% in the placebo group at Week 24.
QUILLIVANT XR is a powder that, after reconstitution with water, forms an extended-release oral suspension formulation of methylphenidate intended for once daily oral administration. QUILLIVANT XR contains approximately 20% immediate-release and 80% extended-release methylphenidate. After reconstitution, QUILLIVANT XR is available in a 25 mg per 5 mL (5 mg per mL) extended-release oral suspension.

Methylphenidate HCl is a central nervous system (CNS) stimulant. The chemical name is methyl α-phenyl-2-piperidineacetate hydrochloride, and its structural formula is shown in Figure 1.

Figure 1: Methylphenidate HCl structure

C14H19NO2•HCI Mol. Wt. 269.77

Methylphenidate HCl is a white, odorless crystalline powder. Its solutions are acid to litmus. It is freely soluble in water and in methanol, soluble in alcohol, and slightly soluble in chloroform and in acetone.

QUILLIVANT XR also contains the following inactive ingredients: sodium polystyrene sulfonate, povidone, triacetin, polyvinyl acetate, sucrose, anhydrous trisodium citrate, anhydrous citric acid, sodium benzoate, sucralose, poloxamer 188, corn starch, xanthan gum, talc, banana flavor, and silicon dioxide.
Systems, methods, and other embodiments associated with data editing in a web-based interactive web response system are described. In one embodiment, a method includes receiving a request to perform an edit on a data field over a web-based protocol. The request is sent to an approval function that accesses stored authorization data to select an approval level associated with the data field. The approval function also determines an authorized approver mapped to the approval level to generate a notification over the web-based protocol. The notification is transmitted to at least one authorized approver over the web-based protocol. Approval to perform the edit is received from the at least one authorized approver over the web-based protocol.
If patient is in the arm "rt-PA + tenecteplase", he will receive tenecteplase (50UI/Kg) treatment. A third MRI will be performed at 24hour that will assess the recanalization status (TIMI), the final volume infarct and the hemorrhagic complications.
A system for locating goods stored in modular hanging units in a storage area. Ordered goods are placed in storage units at a central filling center. The filled storage units are shipped to local storage areas where they are coupled to hook units to form modular hanging units that are then stored on rails in a storage structure. The identifications of the goods and the hanger addresses for the modular hanging units are stored on a local computer database. When a user wants to pick up stored goods, the user inputs the identification or order information for the goods and the computer will search the inventory to locate the goods in a specific stored modular hanger. The modular hanger will be illuminated to facilitate locating the goods.
One devastating manifestation of overactive bladder is urgency incontinence. Although urgency incontinence is a common problem with profound clinical, social and psychological consequences, little is understood about its underlying cause. The involuntary detrusor overactivity (DO) often associated with the disease points to a possible abnormality in voluntary control of the spinobulbospinal voiding reflex by a higher order neuronal network. Recent functional MRI (fMRI) and PET studies have identified increased brain activity during bladder filling and voiding in normal subjects from higher order cognitive control centers. In addition, there are now data to suggest that interactions between these brain areas, which include the pontine micturition center (PMC), periaqueductal gray (PAG), thalamus, insula, dorsal anterior cingulate and prefrontal cortex, may be abnormal in patients with urgency incontinence. Despite these encouraging findings, we do not yet know how these regions are interacting with each other, or to other, unknown but important, regions in the brain. Nor do we know how this interaction might play a role in this disease process. Expanding our knowledge of how these regions are integrated to achieve continence and, importantly, what aspects of this complex circuitry are atypical in patients with urge incontinence is key to our future therapeutic endeavors. With this in mind, the goal of this study is to better characterize the functional integration (i.e. functional connectivity) of the brain's control networks in relation to typical and atypical bladder function. We aim to identify distinct differences in the brain's functional and anatomic topography in women with and without urgency incontinence. Our approach not only has the potential to advance our understanding of the higher level pathophysiology of this disease process, but could also lead to novel more centrally acting therapeutic approaches for treatment of urgency incontinence.
PROBLEM TO BE SOLVED: To obtain a cosmetic excellent in resistance to friction, water repellency, oil repellency, and adherability to the skin, and good in makeup sustainability and feeling when applied, containing a fluorine-contg. compound and a pigment treated with an organosilicon compound. SOLUTION: This cosmetic contains 0.5-20wt.% of a fluorine-contg. compound (pref. a waxy fluorine-contg. polymer) and 0-70wt.% of a pigment treated with an organosilicon compound. The pigment is 25-100 in degree of polymerization and 1-1.3 in molecular weight distribution index, being such one that a reactive alkyl polysiloxane is heat-treated and made to be orientedly adsorbed to one party of the molecular chain ends. This cosmetic can be used as a cosmetic such as eyebrow, eye shadow, cheek rouge, eye liner, mascara, foundation, face powder or lipstick, or as a sunscreen cosmetic. This cosmetic is high in adherability and excellent in spreadability, resistance to water, sebum and friction, being subject to no fading with the lapse of time after makeup.